Propofol‑induced miR‑125a‑5p inhibits the proliferation and metastasis of ovarian cancer by suppressing LIN28B

Zeng,Juan; Li,Yu‑Kun; Quan,Fei‑Fei; Zeng,Xin; Chen,Chang‑Ye; Zeng,Tian; Zou,Juan; Tong,Wen‑Juan

doi:10.3892/mmr.2020.11223

Propofol‑induced miR‑125a‑5p inhibits the proliferation and metastasis of ovarian cancer by suppressing LIN28B

Authors:
- Juan Zeng
- Yu‑Kun Li
- Fei‑Fei Quan
- Xin Zeng
- Chang‑Ye Chen
- Tian Zeng
- Juan Zou
- Wen‑Juan Tong
View Affiliations

Affiliations: Department of Anesthesiology, The Second Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Gynecology, Foshan First People's Hospital, Foshan, Guangdong 528000, P.R. China, Department of Histology and Embryology, Clinical Anatomy and Reproductive Medicine Application Institute, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Gynecology, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China, Department of Obstetrics, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China
Published online on: June 11, 2020 https://doi.org/10.3892/mmr.2020.11223
Pages: 1507-1517
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Propofol, a commonly used intravenous anesthetic agent during surgery, has relatively widespread pharmacological actions. Previous studies have reported that propofol may act as an antitumor drug in several cancer types, such as pancreatic cancer, lung cancer and gastric cancer. However, the underlying mechanism in ovarian cancer remain unknown. Therefore, the present study investigated the pharmacological effect of propofol on microRNAs (miRNAs) in ovarian cancer treatment. Propofol (1, 5 or 10 µg/ml) was used to treat A2780 and SKOV3 ovarian cancer cells for 1, 2, 3, 4 or 5 days. The MTT assay was used to detect cell viability, while wound healing and Transwell assays were utilized to assess the invasive and migratory abilities. The bioinformatics prediction approach identified differentially expressed miRNAs (miRs) that were used in Gene Ontology, Gene Set Enrichment Analysis and Kyoto Encyclopedia of Genes and Genomes analyses. The expression levels of miR‑125a‑5p and lin‑28 homolog B (LIN28B) were evaluated by reverse transcription‑quantitative PCR (RT‑qPCR). A luciferase assay was performed to identify the relationship between miR‑125a‑5p and LIN28B. Western blotting was conducted to measure the protein expression of LIN28B. It was demonstrated that propofol significantly upregulated miR‑125a‑5p to exert its antitumor activity. RT‑qPCR results suggested that propofol could upregulate miR‑125a‑5p and LIN28B expression levels in ovarian cancer cell lines. Western blot analysis also indicated that propofol could enhance the expression of LIN28B in ovarian cancer cell lines. The luciferase assay identified that miR‑125a‑5p could directly inhibit the expression of LIN28B to suppress proliferation and metastasis in ovarian cancer. In conclusion, these results suggested that propofol inhibited ovarian cancer proliferation and metastasis by enhancing miR‑125a‑5p, which targets LIN28B.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D, Jemal A and Ahmedin J: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TÅ, Tervonen H, Thursfield V, Ransom D, Shack L, et al: Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): A population-based study. Lancet Oncol. 20:1493–1505. 2019. View Article : Google Scholar : PubMed/NCBI
4	Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, et al: Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 381:2403–2415. 2019. View Article : Google Scholar : PubMed/NCBI
5	Hsing CH, Lin MC, Choi PC, Huang WC, Kai JI, Tsai CC, Cheng YL, Hsieh CY, Wang CY, Chang YP, et al: Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen species-regulated Akt/IKKβ/NF-κB signaling. PLoS One. 6:e175982011. View Article : Google Scholar : PubMed/NCBI
6	Vasileiou I, Xanthos T, Koudouna E, Perrea D, Klonaris C, Katsargyris A and Papadimitriou L: Propofol: A review of its non-anaesthetic effects. Eur J Pharmacol. 605:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
7	Liu WZ and Liu N: Propofol inhibits lung cancer A549 cells growth and epithelial-mesenchymal transition process by up-regulation of microRNA-1284. Oncol Res. 27:1–8. 2018. View Article : Google Scholar : PubMed/NCBI
8	Du Q, Liu J, Zhang X, Zhang X, Zhu H, Wei M and Wang S: Propofol inhibits proliferation, migration, and invasion but promotes apoptosis by regulation of Sox4 in endometrial cancer cells. Braz J Med Biol Res. 51:e68032018. View Article : Google Scholar : PubMed/NCBI
9	Wang LB, Feng L, He J, Liu B and Sun JG: MiR-125a-5p inhibits the proliferation and invasion of breast cancer cells and induces apoptosis by targeting GAB2. Math Biosci Eng. 16:6923–6933. 2019. View Article : Google Scholar : PubMed/NCBI
10	Cao Y, Shen T, Zhang C, Zhang QH and Zhang ZQ: MiR-125a-5p inhibits EMT of ovarian cancer cells by regulating TAZ/EGFR signaling pathway. Eur Rev Med Pharmacol Sci. 23:8249–8256. 2019.PubMed/NCBI
11	Zhang Z, Zhang S, Ma P, Jing Y, Peng H, Gao WQ and Zhuang G: Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit. Carcinogenesis. 36:937–945. 2015. View Article : Google Scholar : PubMed/NCBI
12	Yong W, Yu D, Jun Z, Yachen D, Weiwei W, Midie X, Xingzhu J and Xiaohua W: Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer. Cell Death Dis. 9:8612018. View Article : Google Scholar : PubMed/NCBI
13	Zhou J, Ng SB and Chng WJ: LIN28/LIN28B: An emerging oncogenic driver in cancer stem cells. Int J Biochem Cell Biol. 45:973–978. 2013. View Article : Google Scholar : PubMed/NCBI
14	Huang J, Cao D, Sha J, Zhu X and Han S: DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer. Biochem Biophys Res Commun. 514:853–860. 2019. View Article : Google Scholar : PubMed/NCBI
15	Wang C, Gu Y, Zhang E, Zhang E, Zhang K, Na Qin N, Dai J, Zhu M, Liu J, Xie K, et al: A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. Oncogene. 38:1611–1624. 2019. View Article : Google Scholar : PubMed/NCBI
16	Dong S, Wang R, Wang H, Ding Q, Zhou X, Wang J, Zhang K, Long Y, Lu S, Hong T, et al: HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res. 38:1102019. View Article : Google Scholar : PubMed/NCBI
17	R Core Team, . R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 2014.
18	Vasaikar SV, Straub P, Wang J and Zhang B: LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 46:D956–D963. 2018. View Article : Google Scholar : PubMed/NCBI
19	Agarwal V, Bell GW, Jin-Wu Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:e050052015. View Article : Google Scholar
20	Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase update 2018: A resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 46:D296–D302. 2018. View Article : Google Scholar : PubMed/NCBI
21	Chen Y and Wang X: miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res. 48:D127–D131. 2020. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zou J, Li H, Huang Q, Liu X, Qi X, Wang Y, Lu L and Liu Z: Dopamine-induced SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma. Tumour Biol. 39:10104283177192722017. View Article : Google Scholar : PubMed/NCBI
24	Zhang J, Zhang D, Wu GQ, Feng ZY and Zhu SM: Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. Hepatobiliary Pancreat Dis Int. 12:305–309. 2013. View Article : Google Scholar : PubMed/NCBI
25	Ye Z, Jingzhong L, Yangbo L, Lei C and Jiandong Y: Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. Oncol Res. 21:201–207. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wijnen JA and Rosenshein NB: Surgery in ovarian cancer. Arch Surg. 115:863–868. 1980. View Article : Google Scholar : PubMed/NCBI
27	Park TW and Kuhn WC: Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther. 4:639–647. 2004. View Article : Google Scholar : PubMed/NCBI
28	Zhang Z, Zang M, Wang S and Wang C: Effects of propofol on human cholangiocarcinoma and the associated mechanisms. Exp Ther Med. 17:472–478. 2019.PubMed/NCBI
29	Wang J, Cheng CS, Lu Y, Ding X, Zhu M, Miao C and Chen J: Novel findings of anti-cancer property of propofol. Anticancer Agents Med Chem. 18:156–165. 2018. View Article : Google Scholar : PubMed/NCBI
30	Huang YH, Lee MS, Lou YS, Lai HC, Yu JC, Lu CH, Wong CS and Wu ZF: Propofol-based total intravenous anesthesia did not improve survival compared to desflurane anesthesia in breast cancer surgery. PLoS One. 14:e02247282019. View Article : Google Scholar : PubMed/NCBI
31	Sun Y, Peng YB, Ye LL, Ma LX, Zou MY and Cheng ZG: Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA 374a/forkhead box O1 signaling axis. Mol Med Rep. 21:1471–1480. 2020.PubMed/NCBI
32	Song J, Shen Y, Zhang J and Lian Q: Mini profile of potential anticancer properties of propofol. PLoS One. 9:e1144402014. View Article : Google Scholar : PubMed/NCBI
33	Peng Z and Zhang Y: Propofol inhibits proliferation and accelerates apoptosis of human gastric cancer cells by regulation of microRNA-451 and MMP-2 expression. Genet Mol Res. 15:152016. View Article : Google Scholar
34	Sun H and Gao D: Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372. BMC Cancer. 18:12522018. View Article : Google Scholar : PubMed/NCBI
35	Zhang W, Wang Y, Zhu Z, Zheng Y and Song B: Propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195. Int J Biol Macromol. 120:975–984. 2018. View Article : Google Scholar : PubMed/NCBI
36	Yang N, Liang Y, Yang P, Yang T and Jiang L: Propofol inhibits lung cancer cell viability and induces cell apoptosis by upregulating microRNA-486 expression. Braz J Med Biol Res. 50:e57942017. View Article : Google Scholar : PubMed/NCBI
37	Huang X, Teng Y, Yang H and Ma J: Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-κB signal. Braz J Med Biol Res. 49:e57172016. View Article : Google Scholar : PubMed/NCBI
38	McManus MT: MicroRNAs and cancer. Semin Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
39	Wu L and Belasco JG: Micro-RNA regulation of the mammalian lin-28 gene during neuronal differentiation of embryonal carcinoma cells. Mol Cell Biol. 25:9198–9208. 2005. View Article : Google Scholar : PubMed/NCBI
40	Wu ZF, Lee MS, Wong CS, Lu CH, Huang YS, Lin KT, Lou YS, Lin C, Chang YC and Lai HC: Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in colon cancer surgery. Anesthesiology. 129:932–941. 2018. View Article : Google Scholar : PubMed/NCBI
41	Ikeda T, Kurasako N, Nishitani K, Okada S and Arai T: Anesthetic management for removal of a giant ovarian tumor using FloTrac X Vigileo monitoring system. Masui. 63:439–442. 2014.(In Japanese). PubMed/NCBI